Since sorafenib is a multikinase inhibitor, it is considered that sorafenib has both direct antiproliferative effect due to the blockade of Raf kinase on tumor cells themselves and indirect effect due to the blockade of receptor tyrosine kinases, such as VEGFR-2, on endothelial cells followed by the inhibition of angiogenesis (5). The gene discussed is KDR; the disease is neoplasm.